Skip to main
Reviews CJC-1295

A scroll-told review of the CJC-1295 research literature — every human pharmacokinetic study, the DAC-versus-no-DAC distinction, and the anti-doping detection record, read in sequence.

How can you find the study behind a claim?

Each CJC-1295 claim points to a full source

The bracketed number matches one source. A PMID is a PubMed catalog number; a DOI is a lasting paper code.

Return to the study reviewSee who made this site

The bracketed number matches a source below

Each number in brackets beside a CJC-1295 claim matches a source below. You will find the Jette 2005, Teichman 2006, and Ionescu/Frohman 2006 studies there. Later sports tests and the 2025 review also appear. You can judge a claim by reading its source.

Some full papers charge a fee. PubMed gives a paper a PMID number, while a DOI is its lasting code. Type either code into an online search for the paper or a public summary. I'd start with the study behind the claim that matters to you.

  1. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. ↗
  2. Jette L, Leger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. ↗
  3. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797. ↗
  4. Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294. ↗
  5. Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res. 2009;19(6):471-477. ↗
  6. Henninge J, Pepaj M, Hullstein I, Hemmersbach P. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Test Anal. 2010;2(11-12):647-650. ↗
  7. An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormone analogs. J Pharm Biomed Anal. 2022. ↗
  8. Advances in the detection of growth hormone releasing hormone synthetic analogs. Drug Test Anal. 2021. ↗
  9. Qualitative identification of growth hormone-releasing hormones in human plasma by means of immunoaffinity purification and LC-MS. Anal Bioanal Chem. 2016. ↗
  10. Aagaard NK, et al. Growth hormone and growth hormone secretagogue effects on nitrogen balance and urea synthesis in steroid treated rats. Growth Horm IGF Res. 2009. ↗
  11. Granata R, Leone S, Zhang X, Gesmundo I, et al. Growth hormone-releasing hormone and its analogues in health and disease. Nat Rev Endocrinol. 2025;21(3):180-195. ↗
  12. CJC-1295 development, pharmacokinetics, and regulatory status: ConjuChem Phase 2 program (NCT00267527, discontinued); 2024 FDA Pharmacy Compounding Advisory Committee review (reviewed, not recommended for the 503A bulks list); WADA Prohibited List Section S2; and the GH/IGF-1-axis safety literature (fluid retention, insulin sensitivity, IGF-1/cancer epidemiology). Composite of primary regulatory and clinical-trial records. ↗
  13. Chromatographic-mass spectrometric analysis of peptidic analytes (2-10 kDa) in doping control. J Mass Spectrom. 2024. ↗
  14. Analysis of growth hormone releasing hormone and its analogs in urine using nano-LC-MS. J Pharm Biomed Anal. 2025. ↗
  15. (2026 peptide therapy safety review). Safety and efficacy of approved and unapproved peptide therapies for musculoskeletal conditions. Sports Med. 2026. ↗
  16. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet. 2004;363(9418):1346-1353. ↗
  17. (GH sodium-retention study). GH increases extracellular volume by stimulating sodium reabsorption in the distal nephron. J Clin Endocrinol Metab. 2002. ↗
  18. (GHRH analog pulsatility/insulin study). Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity. J Clin Endocrinol Metab. 2011. ↗
  19. U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee (PCAC) meeting - briefing document on growth hormone secretagogues (CJC-1295). FDA Advisory Committee Briefing Materials. 2024. ↗
  20. Reference summary. Modified GRF (1-29) - chemical and pharmacological description. Encyclopedic reference. 2024. ↗
  21. World Anti-Doping Agency. The Prohibited List - Section S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics. WADA International Standard. 2025. ↗